Last reviewed · How we verify

Veklury — Competitive Intelligence Brief

Veklury (remdesivir) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleotide analog RNA polymerase inhibitor. Area: Metabolic.

marketed Nucleotide analog RNA polymerase inhibitor SARS-CoV-2 RNA polymerase Metabolic Live · refreshed every 30 min

Target snapshot

Veklury (remdesivir) — Gilead Sciences. Remdesivir is an antiviral nucleotide analog RNA polymerase inhibitor with activity against SARS-CoV-2.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Veklury TARGET remdesivir Gilead Sciences marketed Nucleotide analog RNA polymerase inhibitor SARS-CoV-2 RNA polymerase 2020-01-01
REMDESIVIR REMDESIVIR marketed SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC] 2020-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleotide analog RNA polymerase inhibitor class)

  1. Gilead Sciences · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Veklury — Competitive Intelligence Brief. https://druglandscape.com/ci/remdesivir. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: